Display options
Cite
Castillo V, Pessina P, Hall P, et al. Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome. Open Vet J. 2016;6(1):6-14doi: 10.4314/ovj.v6i1.2.
Castillo, V., Pessina, P., Hall, P., Blatter, M. F., Miceli, D., Arias, E. S., & Vidal, P. (2016). Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome. Open veterinary journal, 6(1), 6-14. https://doi.org/10.4314/ovj.v6i1.2
Castillo, V, et al. "Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome." Open veterinary journal vol. 6,1 (2016): 6-14. doi: https://doi.org/10.4314/ovj.v6i1.2
Castillo V, Pessina P, Hall P, Blatter MF, Miceli D, Arias ES, Vidal P. Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome. Open Vet J. 2016;6(1):6-14. doi: 10.4314/ovj.v6i1.2. Epub 2016 Jan 20. PMID: 26862515; PMCID: PMC4744371.
Copy Download .nbib Format: NLM
Share it on

Open Vet J. 2016;6(1):6-14. doi: 10.4314/ovj.v6i1.2. Epub 2016 Jan 20.

Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome.

Open veterinary journal

V Castillo, P Pessina, P Hall, M F Cabrera Blatter, D Miceli, E Soler Arias, P Vidal

Affiliations

  1. Cat. Clin. Méd. Peq. An. and U. Endocrinología, Escuela Medicina Veterinaria, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires. Av.Chorroarín 280, C. Autónoma de Buenos Aires, Argentina.
  2. Laboratorio de Técnicas Nucleares, Facultad de Veterinaria, Universidad de la República, Lasplaces 1550, Montevideo, Uruguay.
  3. Cat. Cirugía and U. Cirugía, Hosp., Escuela Medicina Veterinaria, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires. Av.Chorroarín 280, C. Autónoma de Buenos Aires, Argentina.

PMID: 26862515 PMCID: PMC4744371 DOI: 10.4314/ovj.v6i1.2

Abstract

The objective of the present study was to compare the effects of isotretinoin 9-cis (RA9-cis) as a post-surgery treatment of thyroid carcinoma to a traditional treatment (doxorubicin) and no treatment. Owners who did not want their dogs to receive treatment were placed into the control group A (GA; n=10). The remaining dogs were randomly placed into either group B (GB; n=12) and received doxorubicin at a dose of 30 mg/m(2) every three weeks, for six complete cycles or group C (GC; n=15) and treated with RA9-cis at a dose of 2 mg/kg/day for 6 months. The time of the recurrence was significantly shorter in the GA and GB compared to GC (P=0.0007; P=0.0015 respectively), while we did not detect differences between GA and GB. The hazard ratio of recurrence between GA and GB compared to GC were 7.25 and 5.60 times shorter, respectively. We did not detect any differences between the other groups. The risk ratio of recurrence was 2.0 times higher in GA compared to GC and 2.1 times higher in GB compared to GC. The type of carcinoma had an effect on time of survival with follicular carcinomas having an increased mean survival time than follicular-compact carcinomas (P<0.0001) and follicular-compact carcinomas had a longer mean survival time than compact carcinomas. The interaction among treatment and type was significant, but survival time in follicular carcinomas did not differ between treatments. In follicular-compact carcinomas the survival time of GC was greater than GB (P<0.05), but we did not detect a difference between GA and GB. In conclusion, this study shows that the use of surgery in combination with RA9-cis treatment significantly increases survival rate and decreases the time to tumor recurrence when compared to doxorubicin treated or untreated dogs. The histological type of carcinoma interacted with treatment for time to recurrence and survival time, with more undifferentiated carcinomas having a worse prognosis than differentiated carcinomas.

Keywords: Differentiated follicular carcinoma; Retinoic acid; Thyroid carcinoma; Thyroid tumour

References

  1. Clin Cancer Res. 2013 Apr 1;19(7):1651-9 - PubMed
  2. Acta Endocrinol (Copenh). 1991 Sep;125(3):291-8 - PubMed
  3. Am J Pathol. 1976 Apr;83(1):61-122 - PubMed
  4. Vet Comp Oncol. 2016 Sep;14 (3):e102-12 - PubMed
  5. Vet Clin North Am Small Anim Pract. 2007 Jul;37(4):789-98, viii - PubMed
  6. Can Vet J. 2007 Jul;48(7):761-3 - PubMed
  7. Vet Pathol. 1991 May;28(3):223-33 - PubMed
  8. Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):775-82 - PubMed
  9. J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 - PubMed
  10. J Clin Endocrinol Metab. 2004 Dec;89(12):6105-11 - PubMed
  11. J Am Vet Med Assoc. 2000 Jun 1;216(11):1775-9 - PubMed
  12. J Clin Endocrinol Metab. 2004 Jan;89(1):272-80 - PubMed
  13. J Vet Intern Med. 2014 Nov-Dec;28(6):1805-13 - PubMed
  14. J Clin Endocrinol Metab. 2012 Oct;97(10):3577-83 - PubMed
  15. J Clin Invest. 2001 Oct;108(8):1123-31 - PubMed
  16. J Am Vet Med Assoc. 2012 Jul 1;241(1):95-103 - PubMed
  17. Curr Pharm Des. 2005;11(19):2525-31 - PubMed
  18. J Small Anim Pract. 2009 Apr;50(4):176-9 - PubMed
  19. J Am Anim Hosp Assoc. 2010 Jul-Aug;46(4):249-54 - PubMed
  20. Aust Vet J. 2005 Apr;83(4):208-14 - PubMed
  21. J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 - PubMed
  22. Biochem Pharmacol. 2009 Mar 15;77(6):979-92 - PubMed
  23. Can Vet J. 2011 Sep;52(9):994-8 - PubMed
  24. Carcinogenesis. 2000 Jul;21(7):1271-9 - PubMed
  25. J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 - PubMed
  26. J Vet Intern Med. 2006 Mar-Apr;20(2):348-54 - PubMed
  27. Rev Endocr Metab Disord. 2009 Jun;10(2):103-9 - PubMed
  28. Endocrinology. 2006 Sep;147(9):4438-44 - PubMed
  29. J Vet Med Sci. 2006 Aug;68(8):797-802 - PubMed
  30. Mol Cell Endocrinol. 2010 Aug 30;325(1-2):110-7 - PubMed
  31. Am J Surg Pathol. 1999 Jun;23(6):678-85 - PubMed
  32. Vet Surg. 1995 Jul-Aug;24(4):315-9 - PubMed
  33. J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 - PubMed
  34. Vet Clin North Am Small Anim Pract. 2007 Jul;37(4):755-73, vii - PubMed
  35. Braz J Med Biol Res. 2011 Jan;44(1):73-7 - PubMed
  36. J Vet Intern Med. 2010 Sep-Oct;24(5):1112-7 - PubMed
  37. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):569-74 - PubMed
  38. Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1798-805 - PubMed
  39. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8 - PubMed

Publication Types